BioCryst Pharma (BCRX) Tops Q2 EPS by 11c, provides product guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.68 -0.23%
EPS Growth %: -43.8%
Financial Fact:
Total revenues: 7.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -43.8%
Financial Fact:
Total revenues: 7.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.06), $0.11 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $109.33 million versus the consensus estimate of $98.3 million.
Guidance:
Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)—
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Honeywell wins $53.9M Navy contract for navigation parts
- Anthropic delays planned IPO from October to November - WSJ
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
